{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:16:21Z","timestamp":1780352181074,"version":"3.54.1"},"reference-count":65,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union","award":["101097094"],"award-info":[{"award-number":["101097094"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Multiple myeloma (MM) is a challenging, B cell malignancy characterised by the uncontrolled proliferation of plasma cells within the bone marrow. Despite significant advances in treatment options nowadays, MM remains an incurable malignancy, with the majority of patients succumbing to the disease. MM develops from a pre-malignant state known as monoclonal gammopathy of unknown significance (MGUS), which then has the potential to evolve either into smouldering (asymptomatic) multiple myeloma (SMM) or into MM. Since novel drug discovery takes years to reach the clinic, drug repurposing, which concerns the detection of existing drugs for a novel disease, can be applied. Methods: To address this critical and still unmet medical need, we present a comprehensive signature-based drug-repurposing approach using all the publicly available bulk transcriptomics datasets on mGUS, sMM, and MM. Results: Our study included an in-house scoring scheme approach enabling further filtering and prioritisation, resulting in 25 candidate repurposed drugs for mGUS, 23 for sMM, and 66 for MM. The corresponding gene targets and the related functional terms have been analysed, providing extra information for stage-specific underlying mechanisms in myeloma. Lastly, enabled by a specific computational workflow, we propose drug combinations between our top candidate repurposed drugs and FDA-approved drugs for MM. Conclusions: Together, these results deliver a stage-specific, transparent resource for MM drug repurposing and combination design, intended to accelerate translation toward earlier disease intervention and improved patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers17183045","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:32:32Z","timestamp":1758187952000},"page":"3045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Computational Drug Repurposing Across the Multiple Myeloma Spectrum: From MGUS to MM"],"prefix":"10.3390","volume":"17","author":[{"given":"Kyriaki","family":"Savva","sequence":"first","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena M.","family":"Bourdakou","sequence":"additional","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Stellas","sequence":"additional","affiliation":[{"name":"Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 11635 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-3430","authenticated-orcid":false,"given":"Jerome","family":"Zoidakis","sequence":"additional","affiliation":[{"name":"Biotechnology Division, Biomedical Research Foundation, Academy of Athens, 10447 Athens, Greece"},{"name":"Biology Department, National and Kapodistrian University of Athens, 10679 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-3363","authenticated-orcid":false,"given":"George M.","family":"Spyrou","sequence":"additional","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, J., Lv, C., Zhou, M., Xu, J.-Y., Chen, B., and Wan, Y. (2022). Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018. Cancers, 14.","DOI":"10.3390\/cancers14194919"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","first-page":"1","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","first-page":"1","article-title":"Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies","volume":"15","author":"Filippatos","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-024-09892-w","article-title":"Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma","volume":"51","author":"Raghunathachar","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104353","DOI":"10.1016\/j.critrevonc.2024.104353","article-title":"Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach","volume":"197","author":"Yang","year":"2024","journal-title":"Crit. Rev. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Abramson, H.N. (2023). Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032645"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., Lagneaux, L., and Covas, D.T. (2013). Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059756"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/gcc.20668","article-title":"A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect","volume":"48","author":"Agnelli","year":"2009","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3324\/haematol.2013.087809","article-title":"Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies","volume":"99","author":"Corchete","year":"2014","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2016.187","article-title":"Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma","volume":"31","author":"McNee","year":"2016","journal-title":"Leukemia"},{"key":"ref_20","unstructured":"R Core Team (2019). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_22","first-page":"100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tomazou, M., Bourdakou, M.M., Minadakis, G., Zachariou, M., Oulas, A., Karatzas, E., Loizidou, E.M., Kakouri, A.C., Christodoulou, C.C., and Savva, K. (2021). Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19. Briefings Bioinform., 22.","DOI":"10.1093\/bib\/bbab114"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Duan, Q., Reid, S.P., Clark, N.R., Wang, Z., Fernandez, N.F., Rouillard, A.D., Readhead, B., Tritsch, S.R., Hodos, R., and Hafner, M. (2016). L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl., 2.","DOI":"10.1038\/npjsba.2016.15"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"W697","DOI":"10.1093\/nar\/gkac328","article-title":"SigCom LINCS: Data and metadata search engine for a million gene expression signatures","volume":"50","author":"Evangelista","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1574-1400(08)00012-1","article-title":"Chapter 12\u2014PubChem: Integrated Platform of Small Molecules and Biological Activities","volume":"4","author":"Bolton","year":"2008","journal-title":"Annu. Rep. Comput. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: An open chemical toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/bioinformatics\/btu624","article-title":"Rcpi: R\/Bioconductor package to generate various descriptors of proteins, compounds and their interactions","volume":"31","author":"Cao","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/bioinformatics\/btz976","article-title":"ChemBioServer 2.0: An advanced web server for filtering, clustering and networking of chemical compounds facilitating both drug discovery and repurposing","volume":"36","author":"Karatzas","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13321-015-0069-3","article-title":"Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?","volume":"7","author":"Bajusz","year":"2015","journal-title":"J. Chemin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"W43","DOI":"10.1093\/nar\/gkz337","article-title":"DrugComb: An integrative cancer drug combination data portal","volume":"47","author":"Zagidullin","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose\u2013Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.7150\/jca.8731","article-title":"Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor","volume":"5","author":"Jurczyszyn","year":"2014","journal-title":"J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","article-title":"FOXM1 regulates glycolysis and energy production in multiple myeloma","volume":"41","author":"Cheng","year":"2022","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2010.08360.x","article-title":"Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers","volume":"152","author":"Richardson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/j.bmcl.2006.01.086","article-title":"Radanamycin, a macrocyclic chimera of radicicol and geldanamycin","volume":"16","author":"Wang","year":"2006","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1568009033481859","article-title":"Development of Radicicol Analogues","volume":"3","author":"Soga","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1562-9","article-title":"The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: Modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors","volume":"10","author":"Abruzzese","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cernuda, B., Fernandes, C.T., Allam, S.M., Orzillo, M., Suppa, G., Chang, Z.C., Athanasopoulos, D., Buraei, Z., and Ai, T. (2019). The molecular determinants of R-roscovitine block of hERG channels. PLoS ONE, 14.","DOI":"10.1101\/644336"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","article-title":"Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II\u2013Dependent Transcription and Down-regulation of Mcl-1","volume":"65","author":"MacCallum","year":"2005","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/ph5091008","article-title":"Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer","volume":"5","author":"Zagouri","year":"2012","journal-title":"Pharmaceuticals"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rashid, M.B.M.A., Toh, T.B., Hooi, L., Silva, A., Zhang, Y., Tan, P.F., Teh, A.L., Karnani, N., Jha, S., and Ho, C.-M. (2018). Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aan0941"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15115","DOI":"10.1073\/pnas.1212802109","article-title":"Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs","volume":"109","author":"Adams","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kung, F.-P., Lim, Y.-P., Chao, W.-Y., Zhang, Y.-S., Yu, H.-I., Tai, T.-S., Lu, C.-H., Chen, S.-H., Li, Y.-Z., and Zhao, P.-W. (2021). Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS\/Akt Pathway in Human Thyroid Cancer Cells. Cancers, 13.","DOI":"10.3390\/cancers13174266"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"73497","DOI":"10.18632\/oncotarget.11988","article-title":"Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells","volume":"7","author":"Yao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ferro, A., Graikioti, D., Gezer, E., Athanassopoulos, C.M., and Cuendet, M. (2023). Entinostat-Bortezomib Hybrids against Multiple Myeloma. Molecules, 28.","DOI":"10.3390\/molecules28031456"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1007\/s12325-021-01835-2","article-title":"Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings","volume":"38","author":"Bash","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biomag.2014.07.004","article-title":"Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro","volume":"4","author":"Yabasin","year":"2014","journal-title":"Biomed. Aging Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1021\/bi100365b","article-title":"The Fungal Product Terreic Acid Is a Covalent Inhibitor of the Bacterial Cell Wall Biosynthetic Enzyme UDP-N-Acetylglucosamine 1-Carboxyvinyltransferase (MurA)","volume":"49","author":"Han","year":"2010","journal-title":"Biochemistry"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kong, C., Huang, H., Xue, Y., Liu, Y., Peng, Q., Liu, Q., Xu, Q., Zhu, Q., Yin, Y., and Zhou, X. (2018). Heterologous pathway assembly reveals molecular steps of fungal terreic acid biosynthesis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-20514-x"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/ijbs.6087","article-title":"The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1038\/s41388-019-0931-2","article-title":"Eph receptor signalling: From catalytic to non-catalytic functions","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: Signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1074\/jbc.M109068200","article-title":"Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with \u03b21 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKC\u03b1 Activation","volume":"277","author":"Podar","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tcb.2021.10.004","article-title":"The amoeboid state as part of the epithelial-to-mesenchymal transition programme","volume":"32","author":"Graziani","year":"2022","journal-title":"Trends Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Saltarella, I., Altamura, C., Lamanuzzi, A., Apollonio, B., Vacca, A., Frassanito, M.A., and Desaphy, J.-F. (2022). Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137302"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Caprio, C., Sacco, A., Giustini, V., and Roccaro, A.M. (2020). Epigenetic Aberrations in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12102996"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.steroids.2009.12.010","article-title":"RSK in tumorigenesis: Connections to steroid signaling","volume":"75","author":"Andrade","year":"2010","journal-title":"Steroids"},{"key":"ref_62","first-page":"4505","article-title":"Oxidative Stress in Multiple Myeloma Pathophysiology and Treatment","volume":"38","author":"Achladas","year":"2024","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kul, A.N., and Kurt, B.O. (2024). Multiple Myeloma from the Perspective of Pro- and Anti-Oxidative Parameters: Potential for Diagnostic and\/or Follow-Up Purposes?. J. Pers. Med., 14.","DOI":"10.3390\/jpm14030221"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Di Costanzo, A., del Gaudio, N., Conte, L., and Altucci, L. (2020). The ubiquitin proteasome system in hematological malignancies: New insight into its functional role and therapeutic options. Cancers, 12.","DOI":"10.3390\/cancers12071898"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Podar, K., and Anderson, K.C. (2010). Targeting the Ubiquitin-proteasome System for the Treatment of Multiple Myeloma and Other Human Diseases. Clin. Med. Insights Ther., 2.","DOI":"10.4137\/CMT.S2889"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:36Z","timestamp":1760035656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":65,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17183045"],"URL":"https:\/\/doi.org\/10.3390\/cancers17183045","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}